Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortCuts off a tumour's blood supply.Sight-saving eye injection for wet macular degeneration.
Body systemCancerEyes
Drug classTargeted antibodiesAnti-VEGF injections
SupplyPrescription onlyPrescription only
Main usesBowel cancer, Lung cancer, Ovarian and cervical cancer, Glioblastoma, Wet macular degeneration (off-label eye injections)Wet age-related macular degeneration, Diabetic macular oedema, Retinal vein occlusion
How it worksStops tumours growing the blood vessels they need.Blocks the signal that grows leaky vessels at the back of the eye.
Starts working——
Half-lifeAbout 20 days—
Typical adult dose5–15 mg/kg IV every 2–3 weeks depending on cancer.2 mg monthly for 3 months, then every 8–16 weeks (8 mg high-dose can extend further).
FormsIV infusion, Intravitreal injection (ophthalmic forms in some countries)Intravitreal injection
Common side effectsHigh blood pressure, Protein in urine, Nosebleeds, TirednessEye redness, Floaters, Eye pain
Serious side effectsBowel perforation, Bleeding, Poor wound healing, ClotsEye infection (endophthalmitis), Retinal detachment, Raised eye pressure
Don't take if——
Alcohol——
PregnancyUsually avoidedContraception for 6 months after.Usually avoidedNot recommended.
Breastfeeding——
In use since20042011
Brand namesUnited States: Avastin, Mvasi, ZirabevUnited Kingdom: Avastin, AlymsysIndia: Bevatas, AbevmyUnited States: Eylea, Eylea HDUnited Kingdom: EyleaIndia: Eylea
Legal status——
ATC codeL01FG01S01LA05

Taken together

No interaction between these medicines is recorded in the atlas.

Open in the interaction checker